Lurasidone for the treatment of major depressive disorder with mixed features: A randomized, double-blind, placebo-controlled study

American Journal of Psychiatry

Volumn 173, Issue 4, 2016, Pages 400-407

  Suppes, Trisha ^a   Silva, Robert ^a   Cucchiaro, Josephine ^a   Mao, Yongcai ^a   Targum, Steven ^a   Streicher, Caroline ^a   Pikalov, Andrei ^a   Loebel, Antony ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; LORAZEPAM; LURASIDONE; PLACEBO; TEMAZEPAM; ZOLPIDEM; NEUROLEPTIC AGENT;

ABDOMINAL DISCOMFORT; ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; HYPOMANIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTOR DYSFUNCTION; NAUSEA; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84962342216     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.15060770     Document Type: Article

References (39)

1. Judd LL, Akiskal HS: The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003; 73:123-131
2. Angst J, Cui L, Swendsen J, et al: Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010; 167:1194-1201
3. Hoertel N, Le Strat Y, Angst J, et al: Subthreshold bipolar disorder in a US national representative sample: prevalence, correlates, and perspectives for psychiatric nosography. J Affect Disord 2013; 146: 338-347
4. Angst J, Azorin JM, Bowden CL, et al: Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry 2011; 68:791-798
5. Angst J, Gamma A, Bowden CL, et al: Evidence-based definitions of bipolar-I and bipolar-II disorders among 5,635 patients with major depressive episodes in the Bridge Study: validity and comorbidity. Eur Arch Psychiatry Clin Neurosci 2013; 263:663-673
6. Benazzi F: Frequency of bipolar spectrum in 111 private practice depression outpatients. Eur Arch Psychiatry Clin Neurosci 2003; 253:203-208
7. Benazzi F, Akiskal HS: Psychometric delineation of the most discriminant symptoms of depressive mixed states. Psychiatry Res 2006; 141:81-88
8. Zimmermann P, Brückl T, Nocon A, et al: Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bi-polarity. Arch Gen Psychiatry 2009; 66:1341-1352
9. Perlis RH, Uher R, Ostacher M, et al: Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry 2011; 68:351-360
10. Perugi G, Angst J, Azorin JM, et al: Mixed features in patients with a major depressive episode: the BRIDGE-II-MIX study. J Clin Psychiatry 2015; 76:e351-e358
11. McIntyre RS, Soczynska JK, Cha DS, et al: The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord 2014; 172C:259-264
12. Nusslock R, Frank E: Subthreshold bipolarity: diagnostic issues and challenges. Bipolar Disord 2011; 13:587-603
13. Akiskal HS, Benazzi F: Psychopathologic correlates of suicidal ideation in major depressive outpatients: is it all due to unrecognized (bipolar) depressive mixed states? Psychopathology 2005; 38:273-280
14. Smith DJ, Forty L, Russell E, et al: Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome. Acta Psychiatr Scand 2009; 119:325-329
15. Benazzi F: Unipolar depression with racing thoughts: a bipolar spectrum disorder? Psychiatry Clin Neurosci 2005; 59:570-575
16. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al: The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013; 170:1249-1262
17. Sani G, Napoletano F, Vöhringer PA, et al: Mixed depression: clinical features and predictors of its onset associated with antidepressant use. Psychother Psychosom 2014; 83:213-221
18. Dudek D, Rybakowski JK, Siwek M, et al: Risk factors of treatment resistance in major depression: association with bipolarity. J Affect Disord 2010; 126:268-271
19. O'Donovan C, Garnham JS, Hajek T, et al: Antidepressant monotherapy in pre-bipolar depression; predictive value and inherent risk. J Affect Disord 2008; 107:293-298
20. Vieta E, Valentí M: Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 2013; 27:515-529
21. Faedda GL, Marangoni C, Reginaldi D: Depressive mixed states: A reappraisal of Koukopoulos' criteria J Affect Disord 2015; 176:18-23
22. Ishibashi T, Horisawa T, Tokuda K, et al: Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxy-tryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010; 334:171-181
23. Hedlund PB: The 5-HT7receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 2009; 206:345-354
24. Cates LN, Roberts AJ, Huitron-Resendiz S, et al: Effects of lurasidone in behavioral models of depression: role of the 5-HT7 receptor subtype. Neuropharmacology 2013; 70:211-217
25. Loebel A, Cucchiaro J, Silva R, et al: Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171:160-168
26. Loebel A, Cucchiaro J, Silva R, et al: Lurasidoneas adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171:169-177
27. First MB, Williams J, Spitzer RL, et al: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). New York, Biometrics Research, New York State Psychiatric Institute, 2007
28. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
29. Guy W: ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
30. Young RC, Biggs JT, Ziegler VE, et al: A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978; 133:429-435
31. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
32. Sheehan DV: The Anxiety Disease. New York, Bantam Books, 1983
33. Posner K, Brown GK, Stanley B, et al: The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168:1266-1277
34. Clayton AH, McGarvey EL, Clavet GJ: The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 1997; 33:731-745
35. Citrome L, Ketter TA, Cucchiaro J, et al: Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2014; 155:20-27
36. Vieta E, Valentí M: Mixed states in DSM-5: implications for clinical care, education, and research. J Affect Disord 2013; 148:28-36
37. Fiedorowicz JG, EndicottJ,Leon AC,et al: Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 2011; 168:40-48
38. Koukopoulos A, Sani G: DSM-5 criteria for depression with mixed features: a farewell to mixed depression. Acta Psychiatr Scand 2014; 129:4-16
39. Gao K, Yuan C, Wu R, et al: Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: areviewofpivotal studies with number neededtotreat. Neurosci Bull 2015; 31:572-588